AD/PD 2026 Immunotherapy Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
flowchart TD
events_adpd_2026_immunotherapy["adpd-2026-immunotherapy"]
events_adpd_2026_immunotherapy["Dates"]
events_adpd_2026_immunotherapy -->|"related to"| events_adpd_2026_immunotherapy
style events_adpd_2026_immunotherapy fill:#81c784,stroke:#333,color:#000
events_adpd_2026_immunotherapy["March"]
events_adpd_2026_immunotherapy -->|"related to"| events_adpd_2026_immunotherapy
style events_adpd_2026_immunotherapy fill:#81c784,stroke:#333,color:#000
events_adpd_2026_immunotherapy["Location"]
events_adpd_2026_immunotherapy -->|"related to"| events_adpd_2026_immunotherapy
style events_adpd_2026_immunotherapy fill:#81c784,stroke:#333,color:#000
events_adpd_2026_immunotherapy["Copenhagen"]
events_adpd_2026_immunotherapy -->|"related to"| events_adpd_2026_immunotherapy
style events_adpd_2026_immunotherapy fill:#81c784,stroke:#333,color:#000
style events_adpd_2026_immunotherapy fill:#4fc3f7,stroke:#333,color:#000
Immunotherapy remains one of the most active areas of drug development for neurodegenerative diseases. AD/PD 2026 featured extensive coverage of antibody-based therapies, active immunization approaches, and next-generation engineering strategies for both Alzheimer's and Parkinson's diseases["@schneider2024"].
Anti-Amyloid Immunotherapies
Approved Therapies
Leqembi (Lecanemab) - Eisai/Biogen ...
AD/PD 2026 Immunotherapy Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
Mermaid diagram (expand to render)
Immunotherapy remains one of the most active areas of drug development for neurodegenerative diseases. AD/PD 2026 featured extensive coverage of antibody-based therapies, active immunization approaches, and next-generation engineering strategies for both Alzheimer's and Parkinson's diseases["@schneider2024"].
Anti-Amyloid Immunotherapies
Approved Therapies
Leqembi (Lecanemab) - Eisai/Biogen The first fully approved disease-modifying therapy for early AD:
CLARITY-AD Results : Continued demonstration of clinical benefitLong-Term Extension : 36-month data showing sustained effectsReal-World Evidence : Post-approval effectiveness dataSafety Management : ARIA monitoring protocols and real-world incidenceCombination Strategies : Trials combining lecanemab with other modalitiesDonanemab - Eli Lilly Trailingblazer program continues to evolve:
TRAILBLAZER-ALZ 2 : Results in broader patient populationsBiomarker Correlations : Amyloid plaque reduction predicts clinical outcomesTreatment Sequencing : Managing patients before and after treatmentSafety Profile : Managing ARIA in clinical practicePipeline Programs
Gantenerumab - Roche : Reformulated delivery and new trial designsCrenezumab - Roche : Anti-amyloid approaches in early populationsRemternetug - Lilly : Next-generation anti-amyloid antibodiesAnti-Tau Immunotherapies
Tau Antibodies in Development Tau immunotherapy has matured significantly[@danysz2023]:
Semorinemab - Roche/Genentech
Phase 2 Results : Safety and efficacy data in early ADMechanism of Action : Targeting extracellular tau speciesBiomarker Endpoints : Tau PET and fluid biomarker correlationsJNJ-63733657 - Janssen
First-in-Human Studies : Early safety and pharmacokineticsTarget Profile : Optimal epitope selectionAbbVie Programs
APNmAb05 : Early-stage anti-tau antibodyTau PET Correlations : Imaging-based patient selectionTau Aggregation Inhibitors
LMTM - TauRx : Phase 3 results and regulatory statusNovel Small Molecules : Next-generation aggregation inhibitorsAlpha-Synuclein Immunotherapies
Passive Immunization Alpha-synuclein antibodies represent a major focus for PD[@masliah2023]:
ABBV-951 - AbbVie
Clinical Development : Subcutaneous anti-alpha-synuclein antibodyMechanism : Targeting toxic alpha-synuclein aggregatesPD Research : Focused on early-stage patientsPrasinezumab - Roche/Prothelia
Phase 2 Results : Safety and efficacy data in early PDMotor Outcomes : Effects on motor symptomsBiomarker Correlations : Alpha-synuclein seed amplificationActive Immunization
PD01A - AFFiRiS
Active Immunization : Vaccine approach for alpha-synucleinImmune Response : Antibody generation against alpha-synucleinSafety Profile : Initial clinical dataNext-Generation Antibody Engineering
Bispecific Antibodies
Tau-Amyloid Bispecifics : Dual-targeting approachesAntibody-Therapeutic Conjugates : Enhanced brain penetrationCross-Disease Applications : Antibodies for both AD and PD targetsFc Engineering
Half-Life Extension : Modified Fc regions for reduced dosingEffector Function Modulation : Optimizing safety profilesBlood-Brain Barrier Penetration : Engineering for enhanced CNS deliveryClinical Trial Design Innovations
Enrichment Strategies
Biomarker-Driven Selection : Amyloid and tau PET for patient selectionGenetic Stratification : Targeting specific genetic subpopulationsStage-Specific Approaches : Optimizing for early vs. advanced diseaseCombination Approaches
Immunotherapy + Small Molecule : Combining antibody therapy with oral drugsImmunotherapy + Gene Therapy : Novel combination strategiesMulti-Antibody Combinations : Simultaneous targeting of multiple proteinsSafety and Biomarkers
ARIA Management
Monitoring Protocols : Advanced MRI and clinical monitoringRisk Factors : Identifying patients at highest riskManagement Strategies : Best practices for ARIA handlingBiomarker Integration
p-Tau217 : Regulatory qualification for trial enrichmentAmyloid PET : Standardized approaches for patient selectionTau PET : For anti-tau therapy developmentKey Takeaways
Anti-amyloid validates — Leqembi and donanemab showing sustained benefitsAnti-tau maturing — Multiple antibodies in late-stage developmentα-Synuclein advancing — Active programs in Parkinson's diseaseEngineering improving — Next-generation antibodies with enhanced propertiesCombination emerging — Immunotherapy combinations in early development
See Also
[AD/PD 2026 Conference](/events/adpd-2026)
[AD/PD 2026 Clinical Trial Updates](/events/adpd-2026-clinical-trials)
[AD/PD 2026 Company Presentations](/events/adpd-2026-company-presentations)
[AD/PD 2026 Emerging Therapeutic Targets](/events/adpd-2026-emerging-therapeutic-targets)
[Events Index](/events/conference-index) Show full description